Oncology On The Go

As part of its Between the Lines™ video series, CancerNetwork® spoke with Liliana Bustamante, MD, hematologist and medical oncologist at Florida Cancer Specialists in Fort Myers, Florida and Richard Kim, MD, service chief of Medical Gastrointestinal Oncology and senior member in the Gastrointestinal Oncology Department at the Moffitt Cancer Center in Tampa, Florida, about the prognostic potential of circulating tumor DNA (ctDNA) as a biomarker for patients with oligometastatic colorectal cancer.
In the video series, Bustamante and Kim discussed the following:
·      Presentation: ctDNA Assays For Patients With CRC Undergoing Resection of Metastases

·      Key Takeaways: ctDNA Assays For Patients With CRC Undergoing Resection of Metastases

·      ctDNA as a Biomarker in CRC

·      ctDNA Assays in CRC: Interpreting Clinical Findings

·      ctDNA Assays in CRC: Impact on Clinical Practice

·      Next Steps in Using ctDNA as a Biomarker in CRC

·      Recap: Prognostic Potential of ctDNA for Oligometastatic Colorectal Cancer

To watch more videos in CancerNetwork®’s Between the Lines™ series, visit cancernetwork.com/between-the-lines.
Don’t forget to subscribe to the “Oncology Peer Review On-The-Go” podcast on Apple Podcasts, Spotify or anywhere podcasts are available.

As part of its OncView™ video series, CancerNetwork® spoke with John Kirkwood, MD, PhD, director of the melanoma center at the University of Pittsburgh Medical Center Hillman Cancer Center, about using immunotherapy for treating melanoma and how to monitor responses in patients properly.
In the video series, Kirkwood discussed the following:
·      Treatment Options for Melanoma

·      Considerations for Immunotherapy Use When Treating Melanoma

·      Monitoring Responses to Melanoma Therapy

·      Pseudoprogression in Melanoma Therapy

·      ctDNA for Melanoma Treatment Monitoring

·      Using ctDNA to Monitor Patients With Melanoma

·      Taking Drug Holidays Amidst Melanoma Therapy

·      Duration of Treatment for Melanoma

To watch more videos in CancerNetwork®’s OncView™ series, visit cancernetwork.com/oncview.
Don’t forget to subscribe to the “Oncology Peer Review On-The-Go” podcast on Apple Podcasts, Spotify or anywhere podcasts are available.

As part of its OncView™ video series, CancerNetwork® spoke with Roy Herbst, MD, PhD, chief of medical oncology at Yale Cancer Center and Smilow Cancer Hospital in New Haven, Connecticut, about currently available treatment options and strategies in immunotherapy for treating non–small cell lung cancer (NSCLC).
In the video series, Herbst discussed the following:

·      Treatment Options in Non–Small Cell Lung Cancer

·      Monitoring Response to Therapy in NSCLC

·      Role of ctDNA in Monitoring Treatment Response in NSCLC

·      Clinical Decision-Making in NSCLC

·      Recap: Monitoring With ctDNA for Immunotherapy Response in Lung Cancer

To watch more videos in CancerNetwork®’s OncView™ series, visit cancernetwork.com/oncview.
Don’t forget to subscribe to the “Oncology Peer Review On-The-Go” podcast on Apple Podcasts, Spotify or anywhere podcasts are available.

This week, CancerNetwork spoke with Matthew Matasar, MD, a lymphoma specialist and chief of the Medical Oncology Service at Memorial Sloan Kettering Cancer Center Bergen, about research from the December issue of ONCOLOGY titled, “Real-World Assessment of Patient Care and Practice Efficiency With the Introduction of Subcutaneous Rituximab.”
The retrospective, observational analysis examined patient care delivery and practice efficiency changes using real-world data. Patients with diffuse large B-cell lymphoma, follicular lymphoma, or chronic lymphocytic leukemia who received a rituximab-containing regimen were eligible for the study.
Matasar touched on subcutaneous rituximab, the role it can play in treatment, the time savings associated with its use, and more.
Don’t forget to subscribe to the “Oncology Peer Review On-The-Go” podcast on Apple Podcasts, Spotify or anywhere podcasts are available.

CancerNetwork spoke with Jun Gong, MD, a practicing medical oncologist who specializes in the treatment of genitourinary cancers at Cedars-Sinai Medical Center, regarding a perspective piece titled, “Cisplatin Neoadjuvant Chemotherapy in an Aging Population With Muscle-Invasive Bladder Cancer.”
Gong’s perspective focuses on an article published in the January issue of ONCOLOGY titled, “Use of Neoadjuvant Chemotherapy in Elderly Patients With Muscle-Invasive Bladder Cancer: A Population-Based Study, 2006-2017.”
In this conversation, Gong overviewed the research and touched on some of the clinically relevant findings. He then detailed his perspective and expanded on cisplatin-based chemotherapy, how age fits into the treatment equation, and where research should focus moving forward in muscle-invasive bladder cancer.

Don’t forget to subscribe to the “Oncology Peer Review On-The-Go” podcast on Apple Podcasts, Spotify or anywhere podcasts are available.

CancerNetwork® recently spoke with Ofer Sharon, MD, CEO of OncoHost, about interim results from the prospective PROPHETIC trial to predict how patients with non–small cell lung cancer respond to immunotherapy.
Sharon first described OncoHost and the mission of this clinical stage precision oncology company. Then, he touched on the key details of this research, with a focus on the PROphet diagnostic platform at the center of this ongoing multicenter clinical trial, as well as what comes next for this research and OncoHost.
Don’t forget to subscribe to the “Oncology Peer Review On-The-Go” podcast on Apple Podcasts, Spotify or anywhere podcasts are available.

CancerNetwork® spoke with Emily Smith, MD, of the Ellis Fishchel Cancer Center, University of Missouri, about a patient case published in the December issue of the journal ONCOLOGY titled, “Metastatic Basal Cell Carcinoma Arising From a Primary Cutaneous Carcinosarcoma.” Smith and colleagues detailed a case regarding a 56-year-old man who the team of care providers diagnosed with metastatic basal cell carcinoma arising from a carcinosarcoma.
In the conversation, Smith talked about what makes this patient case unique, the timeline of this specific patient’s disease and treatment, the rarity of basal cell carcinoma arising from a carcinosarcoma, and plenty more.
Don’t forget to subscribe to the “Oncology Peer Review On-The-Go” podcast on Apple Podcasts, Spotify or anywhere podcasts are available.

CancerNetwork spoke with Matthew Allaway, DO, founder and CEO of Perineologic, about a new prostate cancer biopsy technique that uses the transperineal approach to detect cancer in harder to reach areas of the prostate.

Allaway touched on the American Cancer Society’s annual report that shows the rate of advanced-stage prostate cancer cases are increasing in recent years. He also detailed a companion study to that report, and walked through the specific details and benefits of this biopsy technique.

Don’t forget to subscribe to the “Oncology Peer Review On-The-Go” podcast on Apple Podcasts, Spotify or anywhere podcasts are available.

This week, CancerNetwork closed the book on the year that was 2021. CancerNetwork spoke with Amy Comander, MD, co-medical director and director of breast oncology and cancer survivorship at Mass General Cancer Center, about some of the key developments and data to emerge from 2021 for patients with breast cancer, with a specific focus on the 2021 San Antonio Breast Cancer Symposium (SABCS).
Not only did Comander detail important information from 2021 in the field of breast cancer, but she also touched on how the field is continuously evolving and shared her thoughts on what’s in store for patients in 2022.
Don’t forget to subscribe to the “Oncology Peer Review On-The-Go” podcast on Apple Podcasts, Spotify or anywhere podcasts are available.

As part of its Between the Lines™ video series, CancerNetwork® spoke with Lyudmila Bazhenova, MD, a professor of medicine at the University of California San Diego Health, and Federico Albrecht, MD, an oncologist/hematologist at Miami Cancer Institute, Baptist Health South Florida, about when and how to use real-world evidence when making treatment decisions for patients with EGFR-mutated non–small cell lung cancer (NSCLC).
In the video series, Bazhenova and Albrecht discussed the following:
·      Presentation: Benefits and Limitations of RWE: Lessons From EGFR Mutation-Positive NSCLC

·      EGFR-Mutant NSCLC: Addressing Gaps When Collecting Data

·      Experts in Treating EGFR-Positive NSCLC Compare Randomized Trials and Real-World Studies

·      EGFR-Mutant NSCLC: Incorporating RWE Into Treatment Decisions

·      Referring to Real-World Evidence When Managing EGFR-Mutant NSCLC

·      Using Various Sources of Information to Guide Management of EGFR-Mutated NSCLC

·      Increasing Rates of Real-World Studies in EGFR-Mutated NSCLC

To watch more videos in CancerNetwork®’s Between the Lines™ series, visit cancernetwork.com/between-the-lines.
Don’t forget to subscribe to the “Oncology Peer Review On-The-Go” podcast on Apple Podcasts, Spotify or anywhere podcasts are available.